Scrambler Therapy with Duloxetine for Chemotherapy-Induced Peripheral Neuropathy
This study is testing if Scrambler Therapy, a device that delivers electrical signals to relieve pain, when added to duloxetine-based usual care, can better reduce pain from chemotherapy-induced peripheral neuropathy (CIPN) compared to duloxetine-based usual care alone. CIPN is nerve damage caused by chemotherapy that can lead to pain. Researchers want to see if this combination leads to at least a 50% reduction in pain scores after 35 days. You may be able to join if you are 18 or older, have cancer, and experience significant CIPN pain (at least 4 out of 10). The study aims to enroll 50 participants, but its current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 50 participants. It compares two groups: one receiving Scrambler Therapy plus duloxetine-based usual care, and another receiving only duloxetine-based usual care.
- What's involved
- Participants will undergo questionnaires and physical exams. Scrambler Therapy will be administered by trained staff.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at Day 35 after baseline.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Marcin Chwistek, MD · PRINCIPAL_INVESTIGATOR · Fox Chase Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The difference in the proportion with a 50% reduction in pain scores when comparing the cross-sectionally measured "average" pain score at day 35 with the cross-sectionally measured "average" pain score at baseline (baseline = day 1).At Day 35
Investigate whether Scrambler therapy with duloxetine is superior to duloxetine alone in patient achievement of at least a 50% reduction in pain scores when comparing the cross-sectionally measured "average" pain score at day 35 to the cross-sectionally measured "average" pain score at baseline (baseline = day 1).